Skye Bioscience, Inc. (OTCQB:SKYE), a pharmaceutical company developing a proprietary, synthetic cannabinoid derivative to treat glaucoma, has been advised by its contract manufacturer that it has completed the production of SBI-100 Ophthalmic Emulsion (“SBI-100 OE”) for Skye’s phase 1 clinical trial. The final drug product will be released and available for clinical use in October, following receipt of acceptable results from quality and analytical testing that has been initiated.
“We are pleased to have completed this critical step toward initiating enrollment for our first-in-human study for SBI-100 OE,” stated Punit Dhillon, CEO and chair of Skye. “Our team is scheduled to conduct our clinical site initiation in the second week of October to train staff and investigators of our clinical partner, CMAX, in Australia. Following site initiation and release of SBI-100 OE drug product, we expect dosing in subjects to begin in November.”
